Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Net Income: 2021-2025

Historic Net Income for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$52.8 million.

  • Prime Medicine's Net Income fell 0.60% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 8.97%. This contributed to the annual value of -$195.9 million for FY2024, which is 1.14% up from last year.
  • As of Q3 2025, Prime Medicine's Net Income stood at -$52.8 million, which was down 0.46% from -$52.6 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Net Income peaked at -$16.4 million during Q3 2021, and registered a low of -$65.6 million during Q4 2023.
  • For the 3-year period, Prime Medicine's Net Income averaged around -$50.1 million, with its median value being -$51.9 million (2025).
  • Within the past 5 years, the most significant YoY rise in Prime Medicine's Net Income was 37.54% (2022), while the steepest drop was 78.83% (2022).
  • Quarterly analysis of 5 years shows Prime Medicine's Net Income stood at -$62.9 million in 2021, then skyrocketed by 37.54% to -$39.3 million in 2022, then tumbled by 67.10% to -$65.6 million in 2023, then soared by 35.60% to -$42.3 million in 2024, then decreased by 0.60% to -$52.8 million in 2025.
  • Its last three reported values are -$52.8 million in Q3 2025, -$52.6 million for Q2 2025, and -$51.9 million during Q1 2025.